Welcome to the Office of Health Technology Assessment (OHTA) consultation hub

Use this site to find, share and participate in health technology assessment (HTA) consultations. Input is welcome from consumers, health practitioners and any other interested groups or organisations. 

  • Click on the Pharmaceutical Benefits Advisory Committee (PBAC) link above to provide input about a medicine or vaccine being considered by the PBAC;
  • Click on the Medical Services Advisory Committee (MSAC) link above to provide input about a health service, medical test or device being considered by the MSAC;
  • Or look at the 'Open Consultations' list below.

Consumers and consumer groups and organisations can contact the Consumer Evidence and Engagement Unit for questions on upcoming or current consultations via email: HTAconsumerengagement@health.gov.au

Open consultations

  • Public consultation on items to be considered by the PBAC (July 2024)

    Consultation has opened for the July 2024 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence presented...

    Closes 29 May 2024

  • Public consultation on applications to be considered by the MSAC (August 2024)

    Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 1-2 August 2024. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. ...

    Closes 14 June 2024

Closed consultations

  • Nurse practitioner and midwife PBS prescribing consultation survey

    Consultation is now open for the Review of Pharmaceutical Benefits Scheme (PBS) prescribing by authorised nurse practitioners (notated as ‘NP’ on the PBS schedule) and endorsed midwives (notated as ‘MW’ on the PBS schedule) (the PBS Review). The Department of Health and Aged Care (The Department) is currently undertaking a review for consideration by the Pharmaceutical Benefits Advisory...

    Closed 1 April 2024

  • Public consultation on applications to be considered by the MSAC PASC (April 2024)

    Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 18-19 April 2024. PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies...

    Closed 15 March 2024

  • Health Technology Assessment Policy and Methods Review - Consultation 2

    The Options Paper developed through the Health Technology Assessment Policy and Methods Review (HTA Review) has been published. You can access it through the 'Related' documents link, located at the end of this page. This paper presents options for reform being considered by the Reference Committee to improve Australia’s HTA policies and methods and the funding and approval pathways. ...

    Closed 25 February 2024

  • Public consultation on applications to be considered by the MSAC (April 2024)

    Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 4-5 April 2024. MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application. ...

    Closed 16 February 2024

  • Public consultation on items to be considered by the PBAC (March 2024)

    Consultation has opened for the March 2024 Pharmaceutical Benefits Advisory Committee (PBAC) agenda. The PBAC welcomes input from patients, carers, health professionals, consumer groups or organisations and members of the public on medicines submitted for PBAC consideration. The PBAC considers these public consultation inputs when considering the clinical and economic evidence...

    Closed 31 January 2024